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Preventive Effects of Zoledronic Acid on Bone Metastasis in Mice 
Injected with Human Breast Cancer Cells
Bisphosphonates are used routinely to reduce bone-related events in breast cancer patients 
with bone metastasis. We evaluated the effects of zoledronic acid, a third generation, 
nitrogen-containing bisphosphonate, to prevent bone metastasis in breast cancer. 
Zoledronic acid or vehicle alone was administered to nude mice either simultaneously or 
after intracardiac injection of human breast cancer MDA-MB-231 cells. Nude mice treated 
with zoledronic acid at early time points showed a lower incidence of bone metastases 
than did vehicle-treated nude mice, but these differences were not statistically significant. 
Only 37.5% of mice treated with zoledronic acid at the time of tumor cell inoculation 
developed bone metastases compared to over 51.8% of mice receiving vehicle alone 
(P = 0.304). Cell count of apoptosis confirmed by immunohistochemical staining in 
metastatic bone tissue significantly increased in the zoledronic acid-treated groups 
compared to non-treated group (1,018.3 vs 282.0; P = 0.046). However, metastatic 
tumor cells, which invade soft tissue around the bone, did not show extensive apoptosis; 
there were no differences between the zoledronic acid-treated and control groups. These 
results suggest that zoledronic acid increases apoptosis of metastatic breast tumor cells in 
the bone and could therefore reduce metastatic tumor burden. These results support the 
use of zoledronic acid to reduce the incidence of bone metastasis in breast cancer.
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ORIGINAL ARTICLE
Oncology & Hematology
INTRODUCTION
Breast cancer is the most common malignancy among women, 
and bone metastases occur in approximately 80% of cases of ad-
vanced breast cancer. Bone metastasis in breast cancer is large-
ly osteolytic metastasis coupled with complications such as bone 
pain, pathologic fractures, hypercalcemia, spinal cord compres-
sion, and bone marrow suppression (1-3), which in turn lead to 
increased morbidity and mortality rates in breast cancer patients. 
Osteolytic destruction in breast cancer patients with bone me-
tastasis is caused by the activation of osteoclasts secondary to 
numerous factors secreted by breast cancer cells and the stimu-
lation of osteoclast production by osteoblasts through the recep-
tor activator of nuclear factor-κB ligand (4, 5). Bisphosphonates 
are potent inhibitors of bone resorption that suppress both the 
activities of mature osteoclasts and the formation of new osteo-
clasts (6-9). Therefore, bisphosphonates are being widely used 
in Paget’s disease, osteoporosis, malignancy with hypercalce-
mia, and osteolytic bone metastases (7, 10-13). 
  Zoledronic acid, a third generation nitrogen-containing bis-
phosphonate, is one of the most potent bisphosphonates clini-
cally used at present. It was approved for the treatment of com-
plications associated with osteolytic lesions of metastatic breast 
cancer. As shown in several clinical studies, zoledronic acid re-
duces the incidence of skeletal complications in breast cancer 
patients with confirmed bone metastases (14-16). However, it 
has not yet been used for the primary prevention of bone me-
tastasis in high-risk breast cancer patients. There have been an-
imal studies demonstrating that certain bisphosphonates re-
duce bone metastasis, and it was observed that high-dose pami-
dronate exerts preventive effects in nude mice with osteolytic 
lesions where human breast cancer cells were injected into the 
heart (17-20). Yet, these studies primarily cited a reduction in 
the magnitude of bone metastasis, but did not mention the ef-
fects of bisphosphonates on the development of bone metasta-
sis. If zoledronic acid can be administered safely without caus-
ing serious side effects to reduce bone metastasis in breast can-
cer, it would be clinically meaningful. Given the mechanism of 
action of zoledronic acid on osteoclasts, zoledronic acid should 
have a great potential for the prevention of bone metastasis. Thus, 
preclinical research of zoledronic acid is warranted to explore 
the development of bone metastases in breast cancer.
  The majority of bone metastases that occur in breast cancer 
are osteolytic metastases, which can be diagnosed with radiog-Jeong J, et al.  •  Zoledronic Acid and Bone Metastasis Prevention in Breast Cancer
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raphy. However, when small animals are used, detection of bone 
metastasis is difficult. In addition, very early lesions may be un-
likely viewed on radiography. Thus, in this study, a breast can-
cer cell line, transfected with the luciferase gene, was used; to 
detect metastasized cells, the IVIS
TM imaging system, which en-
ables the detection of early metastatic sites, was used. Further-
more, by comparing the preventive effects of zoledronic acid 
administered at different times, an appropriate administrative 
dosing schedule was explored.
MATERIALS AND METHODS
MDA-MB-231 cell line transfected with luciferase
MDA-MB-231 is a breast cancer cell line that does not express 
estrogen receptors. Cells were incubated in RPMI 1640 (Gibco, 
Grand Island, NY, USA) supplemented with 10% fetal bovine 
serum (FBS; Cansera, Toronto, Ontario, Canada) and antibiotic-
antimycotic (Gibco) in a 5% CO2 incubator. Using lipofectamine 
2000 (Invitrogen, Carlsbad, CA, USA), the cells were cotrans-
fected with GL3-control (Promega, Madison, WI, USA) and TK-
Hygro (Clontech, Mountain View, CA, USA) at a ratio of 1:4. Trans-
fected cells were incubated in hygromycin (200 µg/mL, Invitro-
gen)-containing medium. Resistant colonies were isolated by 
ring cloning. Using Promega Bright-Glo reagent, verification of 
hygromycin-resistant colonies expressing luciferase was per-
formed, with levels expressed as RLU/µg protein. After verifica-
tion, subclones with high luciferase activity were isolated and 
named MDA-MB-231/Luc, which were then incubated in RPMI 
1640 containing 10% FBS.
 
Intracardiac injection of MDA-MB-231/Luc and 
administration of zoledronic acid
These studies (Protocol No. 2011-239) were approved by the In-
stitutional Animal Care and Use Committees of Yonsei Univer-
sity College of Medicine (Seoul, Korea). Five-week-old female 
BALB/c-Foxn1
nu mice (Japan SLC, Shizuoka, Japan) were used. 
For administration of the bisphosphonate, zoledronic acid [1- 
hydroxy-2-(1H-imidazole-1-yl)ethylidene-bisphosphonic acid], 
ZOMETA injection (Novartis Pharmaceuticals Ltd., Basel, Swit-
zerland) was used. Zoledronic acid was stored at 4°C and dilut-
ed with PBS (pH 7.4) prior to use.
  Cells were incubated in fresh medium for 24 hr before injec-
tion. MDA-MB-231/Luc cells were prepared in phosphate-buff-
ered saline (PBS; 5 × 10
5 cells/0.1 mL PBS) and injected into the 
left ventricle of anesthetized mice using 27-gauge needle syringes 
(Fig. 1). Beginning at different times after the injection of cancer 
cells, 120 µg zoledronic acid/kg was administered twice weekly 
for 3 weeks, and all nude mice were sacrificed at week 5 (day 
35). The experiment was undertaken using three different meth-
ods of zoledronic acid administration: administration of zole-
dronic acid for 3 weeks beginning at the time of tumor cell in-
jection (group 1), administration of zoledronic acid for 3 weeks 
beginning 1 week after tumor cell injection (group 2), and ad-
ministration of zoledronic acid for 3 weeks beginning 2 weeks 
after tumor cell injection (group 3). All three corresponding con-
trol groups with no administration of zoledronic acid were ad-
ministered vehicle (PBS) in the same way (Fig. 1).
Detection of MDA-MB-231 cell/Luc in nude mice
MDA-MB-231 cell/Luc was measured at week 5 after injection 
of the tumor cell line. After 5-min anesthesia with ketamine/xy-
lazine, 150 mg D-luciferin/kg (Xenogen Corp., Hopkinton, MA, 
USA) was given to mice by intraperitoneal (IP) injection. After 5 
min, light emitted from bioluminescent tumor cells was mea-
sured using the IVIS
TM imaging system (Xenogen Corp). Mice 
were imaged in both ventral and dorsal views (Fig. 2). After im-
aging at week 5, several sites with bone metastasis were isolated 
from the sacrificed mice, fixed, dehydrated, and hematoxylin 
and eosin (H&E)-dyed for histopathological confirmation of 
bone metastasis.
Terminal deoxynucleotidyl transferase dUTP nick end 
labeling (TUNEL) assay 
The detection of apoptosis was performed using ApopTag, ac-
cording to the instructions of the manufacturer (Chemicon In-
ternational, Inc., Temecula, CA, USA). Briefly, the sections were 
deparaffined, hydrated, treated with proteinase K (20 µg/mL) 
in PBS (pH 7.5) at 37°C for 20 min, and then treated with 3% hy-
droperoxidase in PBS to block endogenous peroxidase. After 
washing with PBS, the slides were incubated with terminal de-
oxynucleotidyl transferase and a nucleotide mixture at 37°C for 
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1 hr and then incubated for 30 min with anti-digoxigenin con-
jugate. The slides were treated with DAB before counterstaining 
with hematoxylin. After dehydration and washing, the sections 
were placed on coverslips and examined by microscopy (Olym-
pus BX 51, Tokyo, Japan).
  Images of slides processed for apoptosis detection were quan-
titatively analyzed using a computerized image analyzer (Meta-
Morph 7.5, Molecular Devices, Sunnyvale, CA, USA). Immu-
nopositive cells in bone from three inconsecutive sections per 
three mice of the zoledronic acid-treated and untreated groups 
were blindly counted with the image analyzer at a magnifica-
tion of  × 400 by an experienced pathologist and expressed as 
the number of cells per 1 mm
3. All values are expressed as the 
means ± standard deviation, and statistical significance was 
evaluated by one-way analysis of variance using SPSS for Win-
dows (version 14.0 SPSS Inc., Chicago, IL, USA)
RESULTS
Effects of zoledronic acid on the prevention of bone 
metastasis
At 35 days after intracardiac injection using the Xenogen IVIS-
200 imaging system, bioluminescence imaging was performed; 
a single hot spot, was considered to have bone metastasis. Fig. 2 
shows an example of bioluminescence imaging. Imaging results 
showed bone metastasis in 14 of 27 mice (51.8%) in the control 
group, 9 of 24 mice in test group 1 (37.5%), 7 of 15 mice in test 
group 2 (46.6%), and 9 of 14 mice in test group 3 (64.2%; Fig. 3). 
Differences between group 1 and control (P = 0.304), between 
group 2 and control (P = 0.747), and between group 3 and con-
trol (P = 0.447) were not statistically significant. The differences 
between each test group were also not statistically significant. 
The number of mice tested in each group differed because some 
mice died during intracardiac injection; other mice showed mas-
sive spillage of injected cancer cells into the pericardial space 
and were therefore excluded. Although results were not statisti-
cally significant, test group 1 treated prophylactically with zole-
dronic acid demonstrated a trend toward a decreased incidence 
of bone metastases. 
Apoptosis of metastatic sites
After identifying sites in which bone metastases occurred in zole-
dronic acid-treated groups and the control group and staining 
with ApopTag peroxidase in situ (Chemicon), the number of 
apoptotic metastatic cells per mm
3 were counted. The apopto-
sis of tumor cells with bone metastasis occurred regardless of the 
timing of zoledronic acid administration. Among the mice that 
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Fig. 2. Metastatic activities visualized using bioluminescent imaging in the control group (A; dorsal side, B; ventral side). First and third mice show hot spots on their ventral sides, 
confirmed as rib metastases.
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Fig. 3. Incidence of bone metastases in each group. Differences between group 1 and 
control (P = 0.304), between group 2 and control (P = 0.747), and between group 3 
and control (P = 0.447) were not statistically significant. Additionally, the differences 
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Fig. 4. Immunohistochemical staining results for apoptosis in metastatic tumor cells in the bone (× 400). ApopTag peroxidase in situ results of metastatic tumor tissues of bone 
in test (A) and control (B) groups. Many apoptotic tumor cells were positively stained in the test groups.
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Fig. 5. Immunohistochemical staining results for apoptosis in metastatic tumor cells outside the bone (× 400). ApopTag peroxidase in situ results of metastatic tumor tissues 
outside the bone in the test (A) and control (B) groups. No differences were seen between the groups.
Apoptotic cell
Apoptotic cell
Fig. 6. Number of apoptotic tumor cells inside and outside of the bone in each group. Apoptosis of metastatic cells increased on average by 1,018.3 in the zoledronic acid-
treated groups (zol) and on average by 282.0 in the control groups (con), indicating a significant increase in apoptosis in the zoledronic acid-treated groups (P = 0.046). On the 
other hand, apoptosis of cells metastasized to the outside of the bone was 173.6 in the zoledronic acid-treated groups and 217.3 in the control groups, suggesting no increase 
in any of the groups and no differences between groups (P = 0.86).
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had bone metastases, we selected three mice from the treated 
(regardless of timing) and control groups, respectively, and apop-
tosis of tumor cells were evaluated as mentioned above (Fig. 4, 5). 
At certain metastatic sites, tumor cells extended to the outside 
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of the bone tissue. Apoptosis of metastatic cells inside the bone 
increased on average by 1,018.3 in the zoledronic acid-treated 
groups and on average by 282.0 in the controls, indicating a sig-
nificant increase in apoptosis in the zoledronic acid-treated 
groups (P = 0.046, Fig. 6). Apoptosis of cells that metastasized 
to the outside of the bone was 173.6 in the zoledronic acid-treat-
ed groups and 217.3 in the controls, suggesting no increase in 
any of the groups and no difference between groups (P = 0.86, 
Fig. 6). 
DISCUSSION
Zoledronic acid, a nitrogen-containing bisphosphonate, exerts 
its pharmacologic activity by inducing apoptosis of osteoclasts; 
it inhibits the mevalonate pathway of osteoclasts and prevents 
the prenylation of small GTP proteins, such as Ras, Rho, and Rab, 
thereby leading to apoptosis (21, 22). The inhibitory effects of 
zoledronic acid on osteolytic metastasis in breast cancer can be 
explained by two mechanisms of action. One mechanism is that 
zoledronic acid reduces the release of growth factors, such as 
insulin-like growth factor and transforming growth factor beta 
(TGF-β), which are abundant in bone matrix by inhibiting osteo-
clasts, which are considered to contribute to the inhibition of 
bone metastasis in breast cancer. The other mechanism is the 
direct apoptotic effects of zoledronic acid on breast cancer cells 
with bone metastasis. High-concentration bisphosphonates have 
been reported to induce apoptosis of cancer cells in the labora-
tory (23-25), and high concentrations of zoledronic acid were 
reported to induce apoptosis in an experiment using 4T1 mouse 
breast cancer cell lines by inhibiting the mevalonate pathway 
(26). In this study, relatively high concentrations of zoledronic 
acid were also used. In general, the dose in mice equivalent to 
the 4 mg intravenous dose in humans is known to be 98-100 
µg/kg (27); in this study, zoledronic acid was administered twice 
a week at 120 µg/kg per dose. Thus, the dose given should be 
taken into consideration for any attempt to apply the results of 
this study to clinical settings.
  In this study, the increased apoptosis of bone metastasis in 
breast cancer in zoledronic acid-treated groups was confirmed, 
and no apoptotic effects of zoledronic acid were observed on 
areas that metastasized to the outside of the bone. This result is 
in line with previous studies citing that bisphosphonates did not 
induce apoptosis in breast cancer cells prior to metastases to 
other organs or on the primary lesions (18). Bisphosphonates 
accumulate primarily in bone when administered intravenous-
ly, thus resulting in higher concentrations in bone than other 
organs. Additionally, bisphosphonates mainly work on bone 
metastasis other than the primary sites or lesions of other organs. 
The apoptotic effects of zoledronic acid on bone metastasis in 
breast cancer can be explained by the aforementioned two mech-
anisms. In this study, zoledronic acid effects on the growth fac-
tors were not fully evaluated. We checked serum TGF-β levels, 
both pre- and post-zoledronic acid treatment in some of mice 
in the zoledronic acid treated groups but there was no definite 
change after zoledronic acid treatment (data not shown). How-
ever, no absolute conclusions can be drawn due to the extremely 
small number of samples and limited number of animals used. 
In addition, it cannot be assumed that changes in TGF-β in the 
areas of bone metastasis would be reflected by serum changes. 
  This study aimed to elucidate whether zoledronic acid could 
reduce the incidence of bone metastasis. Most previous study 
results confirmed that bisphosphonates conferred preventive 
effects on bone metastasis by decreasing the volume of bone 
metastasis (20, 26). However, in a clinical setting, treatments 
begin when bone metastasis is viewed in even one area, which 
considers the presence of bone metastasis. Thus, the incidence 
of bone metastasis may be more important than the volume of 
metastasis. The results of this study showed a trend toward the 
reduction in the incidence of metastasis, although not statisti-
cally significant, in groups in which zoledronic acid was preven-
tively administered. Yet, when zoledronic acid administration 
was delayed, the effects of such decreased incidence were dimin-
ished. Therefore, it may be concluded that the preventive effects 
of zoledronic acid on bone metastasis may no longer exist when 
bone metastasis has already begun. 
  In previous studies, X-rays were used to diagnose bone me-
tastasis. However, X-rays have a low sensitivity for diagnosis of 
bone metastasis in mice, and bone micrometastases may not be 
discovered on X-rays. In fact, it was reported that certain cases 
that were not found to have bone metastasis on X-rays revealed 
to have metastasis by histological examination (20). To overcome 
these limitations, bioluminescence imaging was used to identify 
bone metastasis in this study. The use of green fluorescent pro-
tein was reported to allow a diagnosis 1 week earlier than the 
use of X-rays (28). 
  A more accurate diagnostic method was used to elucidate the 
effects of zoledronic acid on the prevention of bone metastasis 
in this study. However, the mechanism of action of zoledronic 
acid on bone metastasis is associated with the apoptosis of met-
astatic breast cancer cells. Additionally, zoledronic acid does not 
prevent the colonization of breast cancer cells in the bone. There-
fore, the effect of zoledronic acid on the prevention of metasta-
sis involves a decrease in the burden of lesions rather than inci-
dence of metastasis. If the effect on the burden of metastatic le-
sions is large, it may result in a decreased incidence of metasta-
sis, whereas the incidence may not change if the effect on the 
burden of metastatic lesions is small. Several clinical studies of 
the preventive effects on bone metastasis in breast cancer pa-
tients using other bisphosphonates, clodronate or pamidronate, 
have shown both the presence and absence of the preventive 
effects in addition to the presence of preventive effects with no 
statistical significance (29, 30). These contradictory results can Jeong J, et al.  •  Zoledronic Acid and Bone Metastasis Prevention in Breast Cancer
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be explained by the reasons discussed above.
  In summary, the reduced incidence of bone metastasis with 
zoledronic acid, although not statistically significant, was con-
firmed in mice in which breast cancer with bone metastases 
was induced. Apoptosis of tumor cells inside the bone occurred 
to a larger degree in the zoledronic acid-treated group than in 
the control group but was statistically significant. The effects of 
zoledronic acid on the prevention of bone metastasis are asso-
ciated with apoptosis of breast cancer cells at metastatic sites 
inside the bone.
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AUTHOR SUMMARY
Preventive Effects of Zoledronic Acid on Bone Metastasis in Mice Injected with 
Human Breast Cancer Cells
Joon Jeong, Kyung Sun Lee, Yang-Kyu Choi, Young Ju Oh and Hy-De Lee
Bisphosphonates are used routinely to reduce bone-related events in breast cancer patients with bone metastasis. We evaluated 
the effects of zoledronic acid, a third generation, nitrogen-containing bisphosphonate, to prevent bone metastasis in breast 
cancer, using mouse xenograft model. Zoledronic acid decreased incidence of bone metastasis comparing with control, although 
the results were not statistically significant. Apoptosis in metastatic bone tissue significantly increased in the zoledronic acid-
treated groups compared to non-treated group. However, metastatic tumor cells, which invade soft tissue around the bone, did 
not show extensive apoptosis; there were no differences between the zoledronic acid-treated and control groups. These results 
suggest that zoledronic acid increases apoptosis of metastatic breast tumor cells in the bone and could therefore reduce metastatic 
tumor burden. These results support the use of zoledronic acid to reduce the incidence of bone metastasis in breast cancer.